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Introduction 
 
Colorectal cancer is the most common gastrointestinal malignancy and the third leading 
cause of cancer-related death in Western countries (1); in this countries it represents the 
second leading cause of death in both sexes (2,3). More than half of rectal cancer 
patients (pts) have been diagnosed with locally advanced tumour  (LARC: T3/T4 
tumour and/or positive limphonodes) (4). In this cases,  preoperative radiochemotherapy 
(RTCT) followed by total mesorectal excision (TME) is the standard of cure (5,6). 
The aim of neoadjuvant RTCT is to reduce the local recurrence (from 25-40% to less 
than 10%) and to increase the rate of sphincter preservation in pts with low-lying 
tumour, thanks to downstaging and downsizing. Many studies have also shown a benefit 
in overall survival (OS) derived from the use of  preoperative RTCT (6,7). 
Neoadjuvant radiotherapy is generally administered in 28 fractions (Long Course 
Radiotherapy);  in recent years neoadjuvant short course radiotherapy (SRT: 25 Gy in 5 
fractions) has proven effectiveness as long as the long course radiotherapy in terms of 
local recurrence and distant relapses.  Although, SRT seems to be less effective on the 
rate of sphincter preservation in pts with low-lying tumour, due to the little waiting time 
between radiotherapy and surgery (usually around 7-10 days) that does not allow a T 
downsizing (8,9). A delayed surgery could increase that rate (10). 
At present, TME, that involves resection of both the tumor and the surrounding 
mesorectal fat, is the surgical treatment of choice for pts with T2-T4 rectal cancer; when 
associate with preoperative treatment, the recurrence rate is less than 2,4%  at 2 years 
(11,12). 
After neoadjuvant treatment the rate of  histopathologic tumour downstaging and the 
rate of complete pathologic response (pCR) range between 30%-60% and 4%-30%, 
respectively (13,14).  The pathological response has been reported in several studies to 
be closely related to oncologic outcomes (15-18) and many studies (19-21) are trying to 
find predictive factors of complete response to neoadjuvant treatment in order to select 
pts who could benefit from sphincter-preserving procedures or organ-preserving options 
such as local excision of residual tumor or the omission of surgery altogether. 
This could be important to avoid late toxicities related to surgery (either after 
abdominal-perineal resection or after rectal anterior resection) (19-21). 
Recognize in advance whether the patient would respond to neoadjuvant treatment may 
also be useful to decide whether intensify the schedule of preoperative radiotherapy in 
order to improve the downstaging/dowsizing and the rate of pCR. 
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Some studies have shown a correlation between the rate of pCR and many factors: the 
tumor dimension at diagnosis (22,23), the interval between neoadjuvant treatment and 
surgery (24), the carcinoembryonic antigen (CEA) level at diagnosis (25), the distance 
of the tumor from the anal verge before neoadjuvant treatment (26) and the nodal stage 
at diagnosis (23). 
 
To date, however, there is not a real consensus regarding the independent predictive 
factors for achieve a pathological response after neoadjuvant RTCT. Instead, there is a 
greater consensus regarding the prognostic factors and the evaluation of these 
parametres could be useful for deciding whether intensify the schedule of radiotherapy 
and chemotherapy in order to improve the outcomes. 
Many studies regarding prognostic factors in pts with LARC have reported both clinical 
and pathological parameters. The pCR is the main factor that could influenced the local 
and distant rate of relapses (27). Another important parameter is the nodal status: the 
number of pathological positive nodes (28,29), the total number of nodes removed (30-
32) and the nodes ratio (30-32), defined as the number of metastatic nodes divided by 
the total number harvested (30-32). 
Associated with a poor prognosis it is also the circumferential resection margin of 
surgical specimens ≤1mm (33-35). This is related to an higher rate of local recurrence 
and to a worst quality of TME that has been shown to be an independent factor of local 
and overall relapses in some studies (36,37). 
The differentiation grade and/or the mucinous aspects seem to be important prognostic 
factors in the staudy carried out by Qui HZ on ninty-six patints (38) and in the study of  
Oberholzer published in 2012 (39). Both these studies have shown a poor prognosis in 
pts with mucinous tumor and low grade of differentiation.  
The prognostic clinical factors (strumental and haematological) individuated in some 
studies are: the T clinical stage, the tumor size before RTCT (38,40) and the 
pretreatment CEA level (30,40,41). 
 
The primary endpoint of this retrospective analysis was to identify  predictive factors of 
response to neoadjuvant RTCT, which could be used in the next future for treatment 
decision making. The second endpoint was to identify in this subset of pts the 
prognostic factors related to OS and disease free survival (DFS).   
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Materials and methods 
 
In this retrospective study we analyzed the data of 119 pts affected by LARC, without 
evidence of distant metastases, treated with neoadjuvant chemoradiotherapy, between 
January 2008 and April 2014, in Pisa Universitary Hospital. All pts were initially 
submitted to a multidisciplinary discussion (surgeon, medical oncologist, radiation-
oncologist and radiologist). 
Pts characteristics are listed in Table 1. 
All pts were staged by clinical examination (a digital rectal examination, a physical 
examination and a complete history was obtained), total-body tomography (CT), 
rectum-colonscopy and  pelvic magnetic resonance (MRI); many of them were also 
submitted to endorectal ultrasound (EUS).  
For our analysis we restaged all pts according to AJCC cancer staging manual ed.7
th
 
2010. 
Histological diagnosis of rectal cancer was obtained in all pts before the start of 
treatments. 
The planned treatment was neoadjuvant long course RTCT followed by TME-surgery 
+/- adjuvant chemotherapy.  
Clinical T and nodal stage was established by radiologists based on MRI images and/or 
EUS.  
Restaging with pelvic MRI +/- abdominal CT was performed 4 weeks after the end of 
RTCT.  
This analysis was conducted in accordance with: 1) recommendations for physicians 
involved in research on human subjects adopted by the Helsinki declaration of 1964 and 
later revisions and 2) Directive 2001/20/EC April 4, 2001 of the European Parliament. 
The study was also approved by local Medical Ethics Committee. Informed consent was 
obteined in all pts.    
 
Treatment (RTCT and surgery) 
Radiotherapy 
In all pts, before treatment, axial CT images were obtained using a Light Speed RT 16-
slice simulator (GE HealthCare) with a 5mm steps; they were posizioned in prone 
position and in many cases was utilized the belly-board device to displace the small 
bowel out of the treatment field. All pts were treated by 3DCRT (three or four fields) or 
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VMAT technique based on the percentage of small bowel eventually included in high 
level of dose.  
The clinical target volume (CTV) included the rectal tumour with a safety margin of 4-5 
cm, the mesorectum, the presacral and internal iliac nodes. The external iliac nodes 
were included only in T4 tumours for infiltration of anterior pelvic structures; 
obturatory nodes were included if primary tumor was located under the peritoneal 
reflection. For tumors located in the distal rectum, the anal canal was included but 
avoiding the perineal skin. Planning target volume (PTV) consisted of an isotropic 4-
5mm expansion of the CTV. The planned total dose was 5040 cGy (energy level of 6-15 
MV) prescribed at the ICRU point, in 28 fractions of 180 cGy/day, 5 fractions/week.  
 
Concurrent Chemotherapy 
Before the start of chemotherapy, all pts were submitted to a cardiological and 
haemathological evaluation. Blood cells counts was repeated weekly. 
Chemotherapy consisted in continuous infusion of 5-FU at the dose of 225 mg/m2/day 
or capecitabine at dose of 825 mg/m2/BID administered everyday for the entire 
radiotherapy course. 
 
Surgery 
Surgery was planned between 6 and 8 weeks after the end RTCT. All pts were treated by 
the same surgical equipe. The surgical procedure, AR (anterior resection) or APR 
(abdominoperineal resection) with protective ileostomy, was decided by the surgeon and 
in most cases was based on the initial tumour extension and location. TME was 
specifically recommended.  
 
Pathologic evaluation 
Surgical specimens were evaluated according to a standardized procedure. Their 
macroscopic and microscopic characteristics were registered in a specific patient’s 
form, reporting the pathologic stage (UICC classification), the number of examined and 
involved lymph nodes, the status of the margins, the differentiation grade, the presence 
of mucine, the Quirke’s grade (3: intact mesorectum with only minor irregularities of a 
smooth mesorectal surface; 2: moderate bulk to the mesorectum but irregularity of the 
mesorectal suface; 1: little bulk to mesorectum with defects down onto m.propria and/or 
very irregular cirumferential resection margin.) and the Dworak’s tumor regression 
grade (TRG 0 tumor without regression; TRG 1 dominant tumor mass with obvious 
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fibrosis and/or vasculopathy; TRG 2 dominantly fibrotic changes with few tumor cells 
or groups; TRG 3 very few tumor cells in the fibrotic tissue with/without mucous 
substance; TRG 4 fibrotic mass without tumor cells exist).  
 
Postoperative chemotherapy 
The administration of adjuvant chemotherapy was prescribed by the physician 
responsible for the patient based on personal experience.  
When adjuvant chemotherapy  was prescribed, it was administered 3-5 weeks after 
surgery, using 5FU /capecitabine as single agent or 5FU /capecitabine plus oxaliplatin. 
Four-six cycles were generally planned. 
  
Follow-up 
After surgery, all pts were monitored every 4 months for the first year, every 6 months 
until the fifth year and then once a year. The follow-up included clinical examination, 
abdominal ultrasound and chest X-Ray alternated to total body CT scan; rectoscopies 
were prescribed every 6 months for the first 2 years and than yearly; pan-colonoscopies 
were performed at 1, 3 and 5 years from surgery. Local recurrence was defined as any 
tumour reappearance, clinically or histologically proven, occurring in the pelvis or in 
the perineum.  
 
Statistical analysis  
Before testing of inferential statistics, an exploration phase was performed.  
All variables were described by statistical characteristics: categorical data were 
described by frequency and percentage, whereas continuous data by mean, median and 
range. Differences were considered significant at p<0,05. 
The primary endpoint of this retrospective analysis was to identify predictive factors of 
pathological response to neoadjuvant RTCT. The second endpoint was to identify 
prognostic factors related to OS and DFS.   
 Predictive factors of T and N response:  
Based on RM-images, we analyzed T and N characteristics at diagnosis and at restaging 
(before surgery) and their variations. 
For T parameter we considered: clinical stage, T site respect to anal verge (low: ≤ 7cm, 
medium: 7-11 cm, high: >11 cm), cranio-caudal extantion, number of  involved 
quadrants, T volume and the distance from mesorectal fascia. For the last 2 parameters 
we also analyzed the differences between diagnosis and restaging data (ΔT).  
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For N parameter we considered: clinical stage (established by radiologists based on first 
MR and/or EUS with inclusion of all parameters of malingnancy), the number of nodes 
≥ 5mm (short axis diameter) and their distance from mesorectal fascia. 
The time between surgery and the end of RTCT (> or < 8 weeks) was analyzed for both 
T and N predictive factors. 
The univariate analysis was performed by a binary logistic regression. All variables 
significantly influenzing the T and N response in the univariate analysis were analyzed 
together in a multivariate binary logistic regression to assess the independent 
contribution of each predictive factor. The results of the regression model were 
calculated by Wald test and expressed using p-value and both the regression coefficients 
and odds ratio with its related confidence interval.  
 Prognostic factors:  
We analyzed all factors previously described for predictive factors plus age, sex and 
pathological caracteristics (type of surgery, ypT, ypN, total nodes removed, nodes ratio, 
mucinous aspect, grading, state of margins, Quirke grade and Dworak’s tumor 
regression). 
Follow-up length and survival were expressed as median and range. The interval time 
was calculated from the diagnosis. 
The variables were assessed in the DFS and OS univariate survival analysis. Univariate 
survival analysis was performed including each variable in a Cox regression model and 
calculating related p- value by Wald test. All variables significantly influencing survival 
in the univariate analysis were analyzed together in a Cox regression model as 
multivariate analysis, with the aim of studying the independent contribution of each 
variable in explaining survivorship. Furthermore, the proportional hazard was always 
verified by the use of log(-log) curves. The results of the Cox regression were expressed 
using hazard ratios with related confidence intervals and related p-value. 
Differences were considered significant at p<0.05. Analyses were performed using 
SPSS technology v.23. 
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Results 
 
All pts completed the planned radiotherapy. In 88 pts (73,9%) was used 3DCRT 
planning (three or four fields based on dose distribution), in 13 pts (10,9%) VMAT 
(most of all in the last 3 years) and in 18 pts (15,1%) this data was unknow (they 
underwent radiotherapy in other structures). In 38/119 pts (31,9 %) radiotherapy was 
delivered in more than 45 days (median 43 days; range 36-79) but in only 3 pts because 
of toxicities (2 diarrhea G3 and 1 perianal skin toxicity G3). The concurrent 
chemotherapy was not administered in 1 patient bacause of kidney failure; in 17 pts 
(14,3 %) it was interrupped for > 7 days (range 7-30) due to toxicities ≤ G3 (35,3 % 
haematological and 17,6 % gastrointestinal toxicity).  
In most cases was administered concomitant capecitabine (103 pts; 86,5%) and only 16 
pts (13,5%) received i.c. of 5FU.  
The mean time between the end of RTCT and surgery was 8,6 weeks (range: 4,7-15,1). 
Fifteen pts (13,5%), with primary tumor located in the lower part of the rectum, were 
submitted to abdominalperineal resection (APR); 103 pts (86,5%) to anterior resection 
(AR).  
In all pts was confirmed a diagnosis of Adenocarcinoma.  
Downstaging was evaluated by comparing clinical staging and pathological staging. At 
the pathological findings 30 pts had a complete pathological response (25,2%), 60 pts 
(50,4%) a partial T response and 29 pts (24,4%) had a stable disease of the primary 
tumor. No progression disease was observed.  
The TRG was measured using the Dworak scale: TRG4, TRG3, TRG2 and TRG1 was 
obtained in 30 (25,2%), 35 (29,5%), 41 (34,4%) and 13 (10,9%) pts, respectively.  
Seventeen pts (14,3%) had mucinous aspects on the tumor; the grade of differentiation 
was G1, G2 and G3 in 2 (1,7%), 52 (43,7%) and 14 (11,8%) pts, respectively (52 
unknown).   
Four pts (4,4%) had a positive radial margin (≤1mm) and 1 patient (0,8%) had a close 
radial margin (2mm). 
Twenty-five pts (21%) had metastatic nodes at the pathological examination; twenty of 
them (80%) were clinically staged as clinical N+ both by radiologists and by our 
calculation (nodes >5mm at pelvic MR before RTCT). The mean number of removed 
nodes was 21 (range 5-55). (Tab.2)  
Adjuvant chemotherapy was administered in 71 pts (59,7%), three-five weeks after the 
surgery; fortynine pts received a monochemotherapy (5FU or capecitabine) and 22 a 
9 
 
doublet of drugs (5Fu/capecitabine + oxaliplatin).  
After a median follow-up of 50,7 months (range 17,0 - 96,8), one hundred and six pts 
(89,1%) are still alive (90 without evidence of disease, 5 with local recurrence and 11 
with distant metastases). Ten of 13 pts who die had distant relapse without local 
recurrence; the other 3 pts died without evidence of disease (Tab.3).  
The percentage of ypN+ on the pathological findings was 61,9%, 60% and 12,2% in pts 
with distant relapse, local relapse and without recurrences, respectively.   
The probability of overall survival at 2 and 5 years was 97,3% and 88,5%, respectively 
(Fig.1).  
Two and five years DFS was 91,5%  and 77,5%, respectively (Fig.2). 
 
The results in terms of predictive and prognostic factors were analyzed separately. 
 
Predictive Factors 
Based on RM-images, we analyzed T and N characteristics at diagnosis, at restaging 
(before surgery) and their variations. 
We analyzed separately the predictive factors of TRG3-4 (the main and-point) and the 
predictive factors of pathological N0. 
The statistical analysis showed a correlation between TRG3-4 and two of the parameters 
analyzed: the number of involved quadrants at diagnosis (p=0,002) and the cranio-
caudal extension of the tumour at diagnosis (p=0,043). The analysis showed also a trend 
for the volume of the tumor at diagnosis (p=0,122). At the multivariate analysis, the 
number of quadrants resulted as the only parameter statistically significant (p=0,012) 
and the T extension lost is significance (p=0,418). 
These results are shown in Tab.4.   
Regarding to the predictive factors of N0, the analysis showed the correlation with just 
one parameter: the number of nodes ≥ 5mm (smaller diameter). It resulted statistically 
significant both as a continuous variable (p= 0,004 ) and as a dichotomous variable 
(number of nodes <3 vs ≥4; p<0,0001). (Fig. 3).  
These results are shown in Tab.5. 
 
Prognostic Factors 
We analyzed the role of clinical and pathological characteristics in terms of DFS and 
OS. 
Clinical parameters releted to DFS were: the volume of the tumor at diagnosis, both as a 
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continous variable (p=0,046) and as a dichotomous variable (median value of 40cc; 
p=0,015), the number of involved quadrants (p=0,011) and the distance between the 
tumor and the mesorectal fascia, both as dichotomous (cut-off: 1mm; p=0,015) (Fig.4) 
and as continuous variable (p=0,016).  
Pathological parameters related to DFS were: the pathological T stage as continuous (p= 
0,001) and dichotomous variable (T0 vs T1-4; p=0,041 ), the pathological N stage as 
dichotomous parameter (N0 vs N+; p<0,0001) (Fig. 5) and continuous parameter 
(p<0,0001) and the nodal ratio as dichotomous parameter (≤0,2 vs >0,2; p<0,0001). We 
also analyzed the grade of differentiation of the tumor (p=0,045) but we decided to 
avoid it in the multivariate analysis due to the high percentage of unknown date 
(43,7%). Even the TRG parameter resulted statistically correlated to DFS, both as 
dichotomous variable (TRG 1-2 vs TRG 3-4; p=0,041) (Fig. 6) and as continuous 
variable (p= 0,001), but we decided to not analized it in multivariate analysis because of 
its correlation with pathological T stage. 
Our analysis also showed a correlation between DFS and adjuvant chemotherapy in 
favour of those who did it (P= 0,028).   
At the multivariate analysis, the pathological N stage resulted as the only parameter 
statistically significant (p= 0,006); the nodal ratio and the T volume lost their 
significance and the other four parameters analyzed showed a trend of significance. 
These results are shown in Tab.6. 
 
In our analysis, the only clinical parameter releted to OS was the number of involved 
quadrants (p=0,011). Instead, the pathological parameters related with OS were: the 
pathological N stage as dichotomous parameter (N0 vs N+; p=0,009), the number of 
resected nodes both as dichotomous variable (median value: ≤21 vs >21; p=0,048) and 
as continuous variable (p= 0,042) and the nodes ratio as dichotomous parameter (≤0,2 
vs >0,2; p=0,002). 
Our analysis also showed a correlation between OS and adjuvant chemotherapy (P= 
0,005). 
At the multivariate analysis, the pathological N stage (P=0,037), the number of nodes 
resected as dichotomous variable (P=0,049) and the adjuvant chemotherapy (P=0,023) 
resulted as the only parameters statistically significant; the N ratio lost is significance 
(P=0,832) and number of involved quadrants showed a trend toward statistical 
significance (P=0,097). 
These results are shown in Tab.7. 
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Discussion 
 
The primary endpoint of this analysis was to identify predictive clinical parameters of 
pathological response. To know these parameters could be important because pCR 
seems to be related to a better 5-year disease-free survival (86% for TRG4 vs 75% for 
TRG 2-3 and 63% for TRG 0-1) and to a very low rate of local recurrence (near to zero) 
(17). These findings have been corroborated in many studies and a meta-analysis 
including 3105 pts with LARC reported that a pCR after preoperative CTRT was 
associated with a 5-year crude DFS of 83% vs 66% for pts without a complete response 
(42). 
This improvement in systemic and local control in pts with a pCR suggested a 
biological basis for treatment response and that pCR could be a prognostic marker for 
better survival.  
After preoperative RTCT, TME represents the standard treatment with excellent 
oncologic outcomes but this approach (radical surgery after pelvic radiotherapy) could 
be associated with significant toxicity. The rate of perioperative mortality is as high as 
2.4% and postoperative complications occur in over one-third of pts (43,44). Late 
complications related to both surgery and radiotherapy can include bowel obstructions, 
urinary incontinences and bowel and sexual dysfunctions; pts with distal rectal tumors 
may require a permanent colostomy, often associated with poor body image (45). 
Based on the significant rate of pCR after neoadjuvant RTCT (13,14) and the potential 
toxicity of radical surgery, many studies are exploring a conservative menagement 
(“watch-and-wait” approach or local excision) in pts with clinical complete response 
(cCR) or near complete response to RTCT. 
The “watch-and-wait” approach for pts with rectal cancer who achieved a cCR to 
neoadjuvant RTCT was initially described by Brazilian investigators in 2004 (46). 
In an updated series published in 2006, Habr-Gama et al. reported the resultes of 361 pts 
with cT2-T4N0 rectal cancer treated with RTCT (50.4 Gy with concurrent leucovorin 
and  5-FU). At 8 weeks, all pts underwent repeated evaluations, including endoscopies 
with biopsies. The presence of any significant residual ulcer or positive biopsies was 
considered incomplete clinical response and the pts were submitted to radical resection. 
Pts deemed to have a cCR were closely monitored with a monthly serum CEA, digital 
rectal examination (DRE), proctoscopy and biopsy of any suspicious lesion for 1 year, 
then continued under surveillance every 3 months for an additional year and every 6 
months thereafter (47). A total of 99 pts had a sustained cCR for ≥ 12 months and were 
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managed nonoperatively. At a mean follow-up of 60 months, this cohort experienced 13 
(13%) recurrences. Of these, 5 (5%) recurrences were endorectal, 7 (7%) systemic, and 
1 (1%) combined. The 5 isolated endorectal recurrences were effectively salvaged. The 
5-year OS and DFS rate was 93% and 85%, respectively (48). 
In a recent prospective study, the same authors reported that 47/70 pts (68%) analyzed 
demonstrated an initial cCR; eight of them developed a local recurrence in the first 12 
months of follow-up and other four pts had a local relapse > 12 months of follow-up. 
Overall, 35 (50%) pts never underwent surgery due to sustained cCR.(49) 
Recent evidences show that the tumor response to RTCT is time-dependent and that 
tumor regression could take more than 6 weeks (46); the longer interval from the end of 
RTCT was found to be associated with a significantly improved pCR rate in many 
studies (24, 50). Also Petrelli et al (51) showed an improvement of pCR  (19.5% vs 
13.7%) in pts who waited more than 6-8 weeks. 
The omission of surgery is based on the ability to identify pts who have achieved a cCR 
before surgery. Unfortunately, clinical evaluations like DRE, endoscopic assessment and 
imaging modalities, such as CT, MRI or proton emission tomography (PET) are limited 
in their ability to distinguish post-radiation changes from residual disease; none of them 
can identify a cCR with sufficient reliability as a single modality (52,53). 
The question of how to accurately identify pts who have achieved a true pCR is still 
being evaluated and the “watch-and-wait” approach remains investigational. 
The clinical parameters commonly analyzed to predict the pathological complete 
response are: age, gender, clinical T and N stage, T size, circumferential involvment, 
distance from anal verge and interval between RTCT and surgery. 
The initial T size was one of the most common factors identified as predictive for pCR 
(22,23,25,54,55). Some studies indicated 4-5 cm (cranio-caudal extension) as a limit 
value to obtain or not a pCR. Also in our data, the T dimension was indipendentely 
correlated with a pathological response (TRG3-4) as continous variable (inversely 
proportional to TRG3-4, without a significant value of cut-off) and only in the 
univariate analysis (P= 0,043).   
Another variable analyzed in many studies was the number of involved quadrants at 
diagnosis (26,50,54) but it resulted statistically correlated with the rate of pCR only in 
one study wich analyzed 562 pts affected by LARC (54). The results of this study 
indicated that a tumor circumferential extent >60% was associated with a lower pCR 
rate (P=0,033). Also in our analysis the number of involved quadrants seemed to be a 
very significant predictive factor of pCR in the univariate (P=0,002) and in the 
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multivariate analysis (P=0,012). The high significant value of this parameter probably 
mask the significance of the T extension in the multivariate analysis also because they 
are both dimensional measurements.  
In the same study of Das et al (54), the tumor distance from the anal verge resulted as a 
predictive factor of response (P=0,035) and this data was confirmed in the article 
published by Santos in 2016 (P<0,005) (26). In our study this distance was not 
statistically correlated with pathological response (P=0,567); similar data were reported 
in the majority of the studies (23,24,50). 
Regard to the interval between RTCT and surgery, recently considered as important 
predictive factor of response (24,36,50), our data did not confir the direct correlation 
between the time and the rate of pCR (P=0,717), probably because of most pts were 
submitted to surgery in the planned time or a bit longer. Maybe, if we had waited longer 
we would have observed an higher rate of T regression.  
 
Many studies analyzed the role of T and N clinical stage to predict the pathological 
response (23,26,50,54,55) but none showed a statistical correlation. In the study of Park 
CH et al (55) it was examined the data of  249 pts affected by LARC and treated with 
neoadjuvant RTCT and they did not find a correlation between pCR and the clinical T 
and N stage at diagnosis but only with the ycT (p<0,001) and ycN (p<0,001) stage; this 
correlation lost its significance in the multivariate analysis. In our study, we analyzed 
the prognostic value of clinical T and N stage just before neoadjuvant treatment and we 
found a correlation between the initial number of nodes >5mm (lower diameter) and the 
rate of pathological negative nodes; our results showed that pts with a lower number of 
nodes at diagnostic MRI (cut-off: ≥4) had an increased probability of pN0 stage 
(p<0,0001). In our analysis, as well as in the studies cited above (23,26,50,54,55), we 
did not find a correlation between the T clinical stage and the rate of pathological 
response (p=0,200).  
 
The secondary endpoint of our retrospective analysis was to identify the prognostic 
factors related to DFS and OS. 
In pts with LARC, after neoadjuvant RTCT and TME-surgery, the rate of local failure is 
less than 2,4% at 2 years (11,12), moreover the number of distant metastases is still 
high, around 24-30% at 5 years (56); should be therefore necessary to find prognostic 
factors related to DFS and OS in order to improve the therapeutic strategies. 
Pts with high risk of metastases at diagnosis may undergo intensified chemotherapy 
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regimens or may be subjected to earliest systemic treatment (57). Instead, pts with a low 
risk of metastases may avoid chemotherapy and could be treated by intensified 
radiotherapy in order to decrease the percentage of local recurrences.    
Many studies have tried to find clinical and pathological factors related to the rate of 
local and distant relapses in order to classify the pts in “at high” or “at low risk” of 
relapse.   
One of the most important parameters related to the long-term outcome is the pCR; 
many studies showed a close correlation between pCR and the rate of local and distant 
recurrences. Martin S.T. and his colleagues reviewed 16 studies involving 3363 pts and 
showed that pts with pCR were 4 times less likely to develop local failure, 4.3 times 
more likely to be disease free at 5 years and 3.3 times more likely to be survival at 5 
years (16). Also Maas et her colleagues reviewed 484 articles and concluded that pCR 
was related to better DFS and to a lower rate of local recurrences and distant metastases 
(42).  
In our study to evaluate the response to neoadjuvant RTCT,  we used Dworak’s TRG 
and we decided to divide the pts in two groups (TRG1-2 and TRG3-4) because TRG3 
and TRG4 could benefit from conservative menagement or “watch-and-wait” approach. 
Pts with TRG3 and TRG4 had a significant better DFS than pts with TRG1 and TRG2 
(p=0.041). This difference was not evident for OS (p=0.696). Rodel et al, in 2005, 
analyzing Dworak’s TRG separately, had similar results in terms of DFS: pts with 
TRG4, TRG2-3 and TRG0-1 had 86%, 75% and 63% 5 years DFS, respectively 
(p=0.006) (17). 
Regard to T parameter (size, involved quadrants, volume and ypT stage) Luna-Perez on 
61 pts affected by LARC, showed a correlation between tumor size and local relapses 
(35); pts with tumor < 3cm had a lower rate of local recurrences (p=0,039). The same 
author did not report a correlation between T size and distant relapses (p=0,08). In our 
analysis, the initial tumor size was not related to DFS (p=0,235) or to OS (p=0,272), 
while the number of involved quadrants at diagnosis, resulted correlated with DFS 
(p=0,011). 
In our work we analyzed also the prognostic impact of the tumor volume at diagnosis, 
after RTCT and its variation, based on MRI images. Our results showed a correlation 
between the T volume at diagnosis and the DFS (p=0,046) but we decided to not include 
it in the multivariate due to its close correlation with the T size and the number of 
involved quadrants. Inversely, we did not find a correlation between the volume-
parameters and OS; Finally, also the ∆T volume did not seem to correlate with the OS 
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(P=0,960) and DFS (p=0,533). In our study, a bigger initial T volume seemed to be 
related more to local than to distant relapses: all pts (100%) who had local failure had a 
T volume ≥40cc instead, only 3/21 pts (12,3%) who had distant relapses had a T volume 
≥40cc. 
In our analysis we showed a strong correlation between the number of involved 
quadrants at diagnosis and both DFS (p=0,011) and OS (p=0,011) and we noticed that 
pts who developed a local or distant relapse had more likely ≥3 involved quadrants 
(80% and 80,9%)  than those who did not have e relapse (52%). 
As regard to the pathological T stage, in our analysis it was not related to OS (p=0,270) 
but only to DFS (p=0,001). We noticed that none of the pts with local recurrence had a 
pCR vs the 9,5% of them with distant relapses.  The absence of correlation between the 
T stage and the OS could be related, in our opinion, to the low rate of events caused by 
the relatively short follow-up. In the study published by Rodel in 2005 (17) the 
pathological T stage was independently correlated to DFS (p=0,016). 
Regard to the prognostic impact of N parameter (ypN stage, nodes ratio and number of 
resected nodes) many studies showed a correlation between the pathological N stage 
and the rate of local and distant recurrences (17,42,58). In the study published by Rodel 
and his colleagues (17) the ypN was one of the most independent parameter at the 
multivariate analysis (<0,0001).  
In our analysis, we showed a strong correlation of the nodal involvement (ypN+) with 
DFS (p<0,0001) and OS (p=0,009) and this parameter maintained its significance in the 
multivariate analysis, for DFS (p=0,006) as well as for OS (p=0,037). In fact, our 
analysis showed that pts who developed distant or local recurrence had an higher 
percentage of ypN+ (61,9% and 60%) than pts who did not developed a recurrence.  
Some studies analyzed the role of the lymph nodes ratio on the outcome (58,59). 
Leonard and his colleagues, recently, published a work where was shown that pts with 
node ratio > 0,2 had recurrences 4-5 times more likely than pts with node ratio <0,2 
(59). After a reviewed of the literature, we decided to use this cut-off also in our study 
and we found similar results; the node ratio >0,2 was associated with a lower DFS 
(p<0,0001) and OS (p=0,002). In both cases, in the multivariate analysis, this variable 
lost its significance.  
In the study of Pedro Luna-Perez was also analyzed the impact of the total number of 
resected nodes on DFS and OS: when this number was <11 it seemed to be related to 
distant relapses and not to local failures (35). In a study that Zuo conducted on 264 pts 
affected by LARC, the number of resected nodes (cut-off:12) was not correlated with 5 
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years DFS (p=0,87) and OS (p=0,62). In our work we analyzed the same factor and we 
found a correlation only with OS. The reference values analyzed were 12 (p=0,264) and 
21 (the median; p=0,048).     
In Leonard’s study, he showed that the type of surgery and the quality of TME resulted 
connected with the survival (59). Maas and her colleagues confirmed these results in 
their pooled analysis published in 2010; the prognosis of pts submitted to APR was 
poorer than for those who underwent AR (42). 
Another parameter partially dependent to the quality of surgery is the state of the 
circumferential margins that was analyzed by Pedro Luna-Perez in 2005 (35); in this 
analysis it was shown to be related to distant relapses (p=0,02) but not to overall local 
recurrence (p=0,33).     
In our analysis we also looked for a correlation between the type of surgery and 
DFS/OS and we found that pts who underwent Miles had not a lower rate of DFS and 
OS but just a trend of it (p=0,080 and p=0,098). We also analyzed the quality of surgery 
in term of Quirke’s scale and we did not find a correlation with DFS as well as with OS, 
maybe due to the very low number of pts with a bad Quirke’s score (21/119 pts with 
Quirke 2 and 1/119 patient with Quirke 1). This could be also the reason of the absence 
of correlation between the positive radial margins and the local and distant failures. In 
fact, in our group of pts, there were only 5 positive radial margins and they were not 
correlated with DFS (p=0,204) and OS (p=0,611).   
The involvement of the radial margin seems to be related to the distance between the 
tumor and the mesorectal fascia; pts with a distance ≤1mm should undergo to long 
course radiochemotherapy, instead of SCRT, in order to obtain a T downsizing and to 
reduce the rate of positive margins (guidelines AIRO 2012). In our analysis, for this 
reason, we studied the correlation between the T distance from the mesorectal fascia and 
the outcomes; this parameter, continuous as well dichotomous (cut-off:1mm) resulted 
correlated with DFS (p=0,016 and p=0,015) but not with OS (p=0,673). In the 
multivariate analysis it lost its significance and maintained only a trend (p=0,097).  
In the pooled analysis published by Maas in 2010 (42), was analyzed the influence of 
adjuvant chemotherapy on DFS and OS; the administration of chemotherapy did not 
have an effect on DFS, although it was associated with an improved OS. In the 
metanalysis published by Breugom in 2015 (60), which included also the Italian CNR-
study (61) was shown that adjuvant chemotherapy after neoadjuvant RTCT did not 
improve DFS and OS. In our analysis we also analyzed the role of adjuvant treatments 
and we found a better OS (p=0,005) and DFS (p=0,028) in pts who received it. This 
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discrepancy could be due to the casual higher incidence of ypN+ in the group of pts that 
did not undergo to adjuvant chemotherapy (26% vs 17%) and to the rate of pCR that 
was higher in pts submitted to postoperative chemotherapy (28% vs 17%). Finally, we 
had not full data of adjuvant chemotherapy in terms of number of cycles so it could be 
interesting to better evaluate these data in the future.  
 
Conclusions 
 
Our study is retrospective and, thus, has certain inherent limitations.  
know predictive factors of complete or near complete pathological response in pts with 
LARC, after neoadjuvant RTCT, could influence the surgical approach. Many authors 
have analyzed different parameters  predictive of response but their conclusions are 
inhomogeneous; the T size and its distance from the anal verge seem to be two common 
predictive factors of pCR. Based on our results, our opinion is that the number of nodes 
(≥5mm) at diagnosis and the number of involved quadrants could be additional 
predictive parameters. In our study was not possible to analyzed the predictive value of 
the interval between RTCT and surgery but it seems to be an important parameter to 
investigate. 
For these reasons, the question of how to accurately identify pts who have achieved a 
pCR needs further studies, including the analysis of biologic aspects of the tumor; 
“watch-and-wait” approach as well as the local excision remains investigational. 
As regard to the prognostic factors related to DFS and OS, our study is aligned with the 
conclusion of other authors. Analyzing our data, we could conclude that pathological N 
parameters (stage, number of resected nodes and limph nodes ratio) and the number of 
involved quadrants are strongly related to an higher incidence of local and distant 
relapses. Instead, T parameters (the volume and the ypT stage) seem to be related to the 
risk of local recurrence. 
A better knowledge of prognostic factors related to local and distant relapses will be 
necessary to decide whether intensify local or systemic treatments.    
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Figures 
 
 
Fig.1: Overall Survival Curve 
 
 
 
 
Fig.2: Disease Free Survival Curve 
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Fig.3: Clinical N stage as predictive factor of ypN- 
 
 
 
 
 
Fig.4: Distance T-mesorectal fascia as prognostic factor of DFS 
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Fig.5: ypN as prognostic factor of DFS 
 
 
 
 
 
 
Fig.6: Dworak TRG as prognostic factor of DFS 
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 Tab 1. Patients characteristics    
  N° %  
 Patients 119 100  
      Age (median 65 years)    
 ≤ 65  60 50,4  
 > 65  59 49,6  
 Sex    
 Male 77 64,7  
 Female 42 35,3  
 Clinical T stage     
 2 2 1,7  
 3 95 79,8  
 4 22 18,5  
 Clinical N stage 
 
   
 N+ 108 90,7  
 N- 11 9,3  
 N° of involved quadrants    
 1 9 7,5  
 2 44 37,0  
 3 17 14,3  
 4 49 41,2  
 T-anal verge distance (cm)    
 ≤ 7  61 51,3  
 7-11  50 42,0  
 > 11  8 6,7  
 T-mesorectal fascia distance (mm)     
 >1  52 43,7  
 ≤ 1 59 49,6  
 Not evaluable  8 6,7  
 T volume (median 30 cc)      
 ≤ 30  70 58,8  
 > 30  49 41,2  
 T extention (median 50 mm)    
 ≤ 50 75 63,0  
 > 50 44 37,0  
 N  ≥ 5mm  at diagnosis    
 ≥ 4 45 37,8  
 < 4 68 57,1  
 Not evaluable 6 5,1  
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 Tab 2. Pathological characteristics    
  N° %  
 Patients 119 100  
      Type of surgery    
 AR  104 87,4  
 APR (Miles)  15 12,6  
 ypT    
 0 30 25,2  
 1 13 10,9  
 2 41 34,4  
 3 34 28,6  
 4 1 0,9  
 ypN 
 
   
 N+ 25 21  
 N- 94 79  
 N° resected nodes (mean: 21)    
 < 21 64 53,8  
 > 21 55 46,2  
 Nodes ratio (cut-off 0,2)    
 ≤ 0,2  111 93,3  
 > 0,2  8 6,7  
 Mucinous aspect     
 yes  17 14,3  
 No 102 85,7  
 Grading      
 1  2 1,7  
 2  52 43,7  
 3 14 11,8  
 Unknow 51 42,8  
 Positive radial margin    
 Yes 5 4,2  
 No 114 95,8  
 Quirke grade    
 1 1 0,9  
 2 21 17,6  
 3 97 81,5  
 TRG (Dworak)    
 1 13 11  
 2 41 34,4  
 3 35 29,4  
 4 30 25,2  
     
 Tab 3. Local and distant relapses    
  N° %  
 Patients 119 100  
      Local relapses only 5 4,2  
 Distant relapses only 21 17,7  
 Local and distant relapses  0 0  
 Non evidence disease 
 
93 78,1  
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 Tab 4. Predictive factors of TRG 3-4  
   Univariate  Multivariate 
  OR IC 95% P-
value 
RC OR IC 95% p-
value           
Clinical T stage  
(T2-T3-T4) 
0,562 0,233-1,357 0,200     
 
T site  
(low-medium-high) 
0,839 0,478-1,471 0,540     
 
N°of   
involved quadrants 
0,551 0,378-0,802 0,002 -0,527 0,591 0,392-0,891 0,012 
 Distance  
T-anal verge 
1,010 0,976-1,046 0,567     
 
Distance  
T-mesorectal fascia 
1,554 0,951-1,168 0,314     
 
Cranio-caudal  
T extension 
0,979 0,959-0,999 0,043 -0,009 0,991 0,969-1,013 0,418 
 Initial T volume   0,987 0,970-1,004 0,122     
 
∆T volume  0,118 0,992-1,045 0,170     
 Weeks  
RTCT-surgery 
 
 (≤8/>8) 
0,150 0,541-2,445 0,717     
 Costant    2,199 9,020 2,317-35,11 0,418 
         
 Tab 5. Predictive factors of pN0 
   Univariate  Multivariate 
  OR IC 95% P-value RC OR IC 95% p-value 
          Clinical N stage 
 (N+/N-) 
0,933 0,725-1,201 0,592     
 Nodes ≥5mm  
(dic:<4/≥4) 
6,033 2,230-16,18 <0,0001     
 Nodes ≥5mm 
 (continous) 
0,803 0,693-0,932 0,004     
 Distance  
N-mesorectal 
fascia 
1,110 0,917-1,343 0,983     
 Weeks  
RTCT-surgery 
(≤8/>8) 
1,006 0,840-1,195 0,950     
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 Tab 6. Prognostic factors of DFS 
   Univariate  Multivariate 
  HR IC 95% p-value RC HR IC 95% p-value 
          
Age (cut-off:62 years) 1,422 0,490-4,128 0,517     
 
Sex (M/F) 1,199 0,544-2,642 0,653     
 Clinical N stage 
(N+/N-) 
0,734 0,220-2,452 0,615     
 Clinical T stage 
(T2-T3-T4) 
1,482 0,628-3,495 0,369     
 T site 
(low-medium-high) 
0,673 0,351-1,288 0,232     
 
Involved quadrants  1,727 1,131-2,638 0,011 0,399 1,491 0,871-2,550 0,145 
 
T-anal verge 
distance(cm) 
0,994 0,980-1,009 0,448     
 T-mesorectal 
fascia(mm) 
 
0,706 0,533-0,936 0,016 -0,126 0,881 0,759-1,023 0,097 
 
T extension 1,010 0,993-1,028 0,235     
 T volume 
(cut-off : 40cc) 
 
2,710 1,216-6,042 0,015 0,346 1,413 0,533-3,743 0,487 
 
∆T volume 0,992 0,969-1,016 0,533     
 
ypN (N+/N-) 8,650 3,903-19,17 <0,0001 1,539 4,659 1,561-13,911 0,006 
 
ypT (continuous) 2,360 1,450-3,843 0,001 0,485 1,624 0,834-3,164 0,154 
 Type of surgery 
(APR/AR) 
0,442 0,167-1,102 0,080     
 
Mucinous aspect 0,802 0,241-2,671 0,719     
 
Grading 2,7 1,021-7,142 0,045     
 Quirke 
 
 
1,342 0,476-3,785 0,578     
 TRG 
(TRG3-4/TRG1-2) 
4,485 1,060-18,98 0,041     
 
TRG (continuous) 0,494 0,319-0,763 0,001     
 
Radial margin 2,550 0,602-10,81 0,204     
 
Resected  nodes  0,979 0,935-1,024 0,353     
 
Nodes ratio 
(cut-off:0,2) 
10,162 4,005-25,78 <0,0001 0,498 1,645 0,407-6,653 0,485 
 Adjuvant 
chemotherapy 
0,404 0,179-0,909 0,028 -0,791 0,453 0,174-1,183 0,106 
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 Tab 7. Prognostic factors of OS 
   Univariate  Multivariate 
  HR IC 95% p-value RC HR IC 95% p-value 
          Age  
(cut-off:62years) 
1,079 1,012-1,150 0,099     
 Sex (M/F) 2,090 0,667-6,545 0,206     
 Clinical N stage  
(N+/N-) 
4,572 1,463-14,28 0,009     
 Clinical T stage  
(T2-T3-T4) 
1,352 0,628-3,495 0,369     
 T site  
(low-med-high) 
0,673 0,792-2,309 0,270     
 Involved 
quadrants  
2,738 1,260-5,948 0,011 0,667 1,948 0,887-4,279 0,097 
 T-anal verge 
distance(cm) 
0,997 0,978-1,017 0,794     
 T-mesorectal 
fascia(mm) 
 
0,964 0,814-1,142 0,673     
 T extension 1,013 0,990-1,037 0,272     
 T volume  
(diagnosis) 
 
1,001 0,961-1,043 0,960     
 ∆T volume 0,992 0,969-1,016 0,533     
 ypN (N+/N-) 4,572 1,463-14,18 0,009 1,633 5,120 1,100-23,83 0,037 
 ypT  
(continuous) 
1,352 0,792-2,309 0,270     
 Type of surgery 
(APR/AR) 
0,364 0,110-1,205 0,098     
 Mucinous  
aspect 
0,647 0,083-5,061 0,678     
 Grading 0,518 0,032-8,387 0,643     
 Quirke 
 
 
0,785 0,230-2,679 0,699     
 TRG  
(TRG3-4/TRG1-2) 
1,305 0,343-4,973 0,696     
 TRG  
(continuous) 
0,858 0,469-1,570 0,619     
 Radial margin 1,705 0,218-13,33 0,611     
 Resected nodes  
(cut-off:21) 
0,127 0,016-0,983 0,048 -2,093 0,123 0,015-0,992 0,049 
 Nodes ratio  
(cut-off:0,2) 
8,146 2,134-31,10 0,002 -0,209 0,811 0,118-5,571 0,832 
 Adjuvant  
chemotherapy 
0,102 0,020-0,511 0,005 -1,966 0,140 0,026-0,758 0,140 
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